![Michael P. Doyle](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael P.
Doyle worked as a Senior Director of Regulatory Affairs at Clovis Oncology, Inc. and as the Head of Regulatory Affairs at Novella Clinical, Inc. He also worked as the Vice President of Regulatory Affairs at Fresh Tracks Therapeutics, Inc. from 2016 to 2022.
Doyle holds a doctorate degree from the University of New Mexico School of Medicine.
| Unternehmen | Position | Ende |
|---|---|---|
| FRESH TRACKS THERAPEUTICS, INC. | General Counsel | 01.07.2022 |
Novella Clinical, Inc.
 Novella Clinical, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical research development solutions | General Counsel | - |
| CLOVIS ONCOLOGY, INC. | General Counsel | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as an biopharmaceutical company that acquires, develops and commercializes innovative anti cancer agents | Health Technology |
University of New Mexico School of Medicine
 University of New Mexico School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novella Clinical, Inc.
Novella Clinical, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical research development solutions | Commercial Services |
Fresh Tracks Therapeutics, Inc.
 Fresh Tracks Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates pharmaceutical company that develops and manufactures prescription therapeutics products for the treatment of autoimmune, inflammatory and debilitating diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
